Constrained peptide models from phage display libraries highlighting the cognate epitope-specific potential of the anti-HIV-1 mAb 2F5

Immunology Letters

Volumn 136, Issue 1, 2011, Pages 80-89

  Palacios Rodríguez, Yadira ^a   Gazarian, Tatiana ^b   Huerta, Leonor ^a   Gazarian, Karlen ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Epitope; HIV 1; MAb 2F5; Mimotope; Phage display

Indexed keywords

ASPARTIC ACID; EPITOPE; IMMUNOGLOBULIN G; LEUCINE; MONOCLONAL ANTIBODY 2F5; PEPTIDE LIBRARY; RABBIT ANTISERUM; TRYPTOPHAN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANTIBODY COMBINING SITE; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BACTERIOPHAGE M13; COMBINATORIAL LIBRARY; CONTROLLED STUDY; FEMALE; IMMUNOGENICITY; LIGAND BINDING; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PHAGE DISPLAY; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 79952313157     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.12.008     Document Type: Article

References (46)

1. Buchacher A., Predl R., Strutzenberger K., Steinfellner W., Trkola A., Purtscher M., et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994, 10:359-369.
2. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.D., Binley J.M., et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001, 75:10892-10905.
3. Zwick M.B., Wang M., Poignard P., Stiegler G., Katinger H., Burton D.R., et al. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol 2001, 75:12198-12208.
4. Binley J.M., Wren T., Korber B., Zwick M.B., Wang M., Chappey C., et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004, 78:13232-13252.
5. Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D., et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999, 73:4009-4018.
6. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6:207-210.
7. Mascola J.R. Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 2002, 20:1922-1925.
8. Muster T., Guinea R., Trkola A., Purtscher M., Klima A., Steindl F., et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 1994, 68:4031-4034.
9. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993, 67:6642-6647.
10. Conley A.J., Kessler J.A., Boots J., Tung S., Arnold B.A., Keller P.M., et al. Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-GP41 human monoclonal antibody. Proc Natl Acad Sci USA 1994, 91:3348-3352.
11. Purtscher M., Trkola A., Grassauer A., Schulz P., Klima A., Döpper S., et al. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. AIDS 1996, 10:587-593.
12. Pai EF, Klein MH, Chong P, Pedyczak A. Fab'-epitope complex from the HIV-1 cross-neutralizing monoclonal antibody 2F5, World Intellectual Property Organization (http//www.wipo) patent WO-00/61618; 2000.
13. Ofek G., Tang M., Sambor A., Katinger H., Mascola J.R., Wyatt R., et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004, 78:10724-10737.
14. Barbato G., Bianchi E., Ingallinella P., Hurni W.H., Miller M.D., Ciliberto G., et al. Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J Mol Biol 2003, 330:1101-1115.
15. Julien J.P., Bryson S., Nieva J.L., Pai E.F. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site. J Mol Biol 2008, 384:377-392.
16. Bryson S., Julien J.P., Hynes R.C., Pai E.F. Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications. J Virol 2009, 83:11862-11875.
17. Zwick M.B., Jensen R., Church S., Wang M., Stiegler G., Kunert R., et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10, require surprisingly few crucial residues in the membrane - proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 2005, 79:1252-1261.
18. Parker C., Deterding L., Hager-Braun C., Binley J.M., Schülke N., Katinger H., et al. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J Virol 2001, 75:10906-10911.
19. McGaughey G.B., Citron M., Danzeisen R.C., Freidinger R.M., Garsky V.M., Hurni W.M., et al. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. Biochemistry 2003, 42:3214-3223.
20. Joyce J.G., Hurni W.M., Bogusky M.J., Garsky V.M., Liang X., Citron M.P., et al. Enhancement of alpha-helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design. J Biol Chem 2002, 277:45811-45820.
21. Tian Y., Ramesh C.V., Ma X., Naqvi S., Patel T., Cenizal T., et al. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing antibody 2F5: effects of side chain and backbone modifications and conformational constraints. J Pept Res 2002, 59:264-276.
22. Menendez A., Chow K.C., Pan O.C., Scott J.K. Human Immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope. J Mol Biol 2004, 338:311-327.
23. Ho J., MacDonald K.S., Barber B.H. Construction of recombinant targeting immunogens incorporating an HIV-1 neutralizing epitope into sites of differing conformational constraint. Vaccine 2002, 20:1169-1180.
24. Ho J., Ugen R.A., Zwick M.B., Luscher M.A., Barber B.H., McDonald K.S. Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response. Vaccine 2005, 23:1559-1573.
25. Liang X., Munshi S., Shendure J., Mark G., Davies M.E., Freed D.C., et al. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. Vaccine 1999, 17:2862-2872.
26. Coëffier E., Clément J.M., Cussac V., Khodaei-Boorane N., Jehanno M., Rojas M., et al. Antigenicity and immunogenicity of the HIV-1 GP41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine 2000, 19:684-693.
27. Ofek G., McKee K., Yang Y., Yang Zh., Skinner J., Guenaga F.J., et al. Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of the heavy chain third complementary - determining region. J Virol 2010, 84(6):2955-2962.
28. Smith G.P., Scott J.K. Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol 1993, 217:228-257.
29. Gazarian T.G., Selisko B., Gurrola G.B., Hernández R., Possani L.D., Gazarian K.G. Potential of peptides selected from phage-displayed libraries to mimic conformational epitopes: a study on scorpion toxin Cn2 and the neutralizing monoclonal antibody BCF2. Comb Chem High Throughput Screen 2003, 6(2):119-132.
30. Galfrè G., Monaci P., Nicosia A., Luzzago A., Felici F., Cortese R. Immunization With phage-displayed mimotopes. Methods Enzymol 1996, 267:109-115.
31. Huerta L., Lamoyi E., Baéz-Saldaña A., Larralde C. Human Immunodeficiency virus envelope-dependent cell-cell fusion: a quantitative fluorescence cytometric assay. Cytometry 2002, 47(2):100-105.
32. Huerta L., Gómez-Icazbalceta G., Soto-Ramírez L., Rodriguez R., Fuentes L., Lamoyi E., et al. Human immunodeficiency virus 1 (HIV-1) envelope-dependent cell-cell fusion modulation by HIV-positive sera is related to disease progression. J Gen Virol 2005, 86(7):1961-1966.
33. López-Balderas N., Huerta L., Villareal C., Rivera-Toledo E., Sandoval G., Larralde C., et al. In vitro cell fusion between CD4(+) and HIV-1 Env(+) T cells generates a diversity of syncytia varying in total number, size and cellular content. Virus Res 2007, 123(2):138-146.
34. Huerta L., López-Balderas N., Rivera-Toledo E., Sandoval G., Gómez-Icazbalceta G., Villareal C., et al. HIV-envelope-dependent cell-cell fusion: quantitative studies. ScientificWorldJournal 2010, 9:746-763.
35. Rivera-Toledo E., López-Balderas N., Huerta L., Lamoyi E., Larralde C. Decreased CD4 and wide-ranging expression of other immune receptors after HIV-envelope-mediated formation of syncytia in vitro. Arch Virol 2010, 155(8):1205-1216.
36. Cao J., Park I.W., Cooper A., Sodroski J. Molecular determinants of acute single cell lysis by human immunodeficiency virus type 1. J Virol 1996, 70(3):1340-1354.
37. Montero M., van Houten N.E., Wang X., Scott J.K. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 2008, 72(1):54-84.
38. Ofek G., Guenaga F.J., Schief W.R., Skinner J., Baker D., Wyatt R., et al. Elicitation of structure-specific antibodies by epitope scaffolds. Proc Natl Acad Sci USA 2010, 107(42):17880-17887.
39. Manivel V., Sahoo N.C., Salunke D.M., Rao K.V.S. Maturation of an antibody response is governed by modulations in flexibility of the antigen-combining site. Immunity 2000, 13(5):611-620.
40. Langman R.E. The specificity of immunological reactions. Mol Immunol 2000, 37:555-561.
41. Enshell-Seijffers D., Smelyanski L., Vardinon N., Yust I., Gershoni J.M. Dissection of the humoral response towards an HIV epitope: a model for the analysis of antibody diversity in HIV+ individuals. FASEB J 2001, 15:2112-2120.
42. Palacios-Rodríguez Y., Gazarian T., Rowley M., Majluf-Cruz A., Gazarian K. Collection of phage-peptide probes for HIV-1 immunodominant loop-epitope. J Microbiol Methods 2007, 68:225-235.
43. Rejto P.A., Verkhivker G.M. Unraveling principles of lead discovery: from unfrustrated energy landscapes to novel molecular anchors. Proc Natl Acad Sci USA 1996, 93:8945-8950.
44. Gazarian K. Drug discovery and design via high throughput screening of combinatorial phage-display protein-peptide libraries. Frontiers in drug design & discovery 2005, v1:29-67. Bentham Science Publishers.
45. Lorizate M., Gomara M.J., de la Torre B.G., Andreu D., Nieva J.L. Membrane-transferring sequences of the HIV-1 gp41 ectodomain assemble into an immunogenic complex. J Mol Biol 2006, 360:45-55.
46. Sáez-Cirión A., Nir S., Lorizate M., Agirre A., Cruz A., Pérez-Gill J., et al. Sphingomyelin and cholesterol promote HIV-1 gp41 pretransmembrane sequence surface aggregation and membrane restructuring. Biol Chem 2002, 277(24):21776-21785.